Related Experiment Video
Updated: Jun 24, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Drug-induced parkinsonism.
Frandy Susatia1, Hubert H Fernandez
1Hubert H. Fernandez, MD McKnight Brain Institute, 100 South Newell Drive, Room L3-100, PO Box 100236, Gainesville, FL 32610-0236, USA. fernandez@neurology.ufl.edu.
Current Treatment Options in Neurology
|April 15, 2009
Summary
Drug-induced parkinsonism (DIP) mimics Parkinson's disease, primarily causing rigidity and bradykinesia. Stopping the offending drug is the main treatment, though further research is needed for other options.
Area of Science:
- Neurology
- Pharmacology
Background:
- Drug-induced parkinsonism (DIP) presents symptoms similar to Parkinson's disease, including rigidity and bradykinesia.
- It is primarily caused by drugs blocking dopamine D2 receptors, with other proposed mechanisms involving dopamine depletion and GABAergic system overactivity.
Purpose of the Study:
- To review the characteristics, causes, and management of drug-induced parkinsonism.
- To highlight the importance of appropriate neuroleptic prescription and the potential role of atypical antipsychotics.
Main Methods:
- Literature review and synthesis of existing knowledge on drug-induced parkinsonism.
- Analysis of postulated mechanisms, clinical presentation, and treatment strategies.
Main Results:
- DIP onset is acute to subacute, more common in women, with a bimodal age distribution.
- Risk is reduced but not eliminated with atypical antipsychotics, especially in vulnerable populations like the elderly or cognitively impaired.
Conclusions:
- Discontinuation of the causative medication is the primary treatment for DIP.
- Further prospective studies are essential to elucidate DIP mechanisms, identify susceptibility factors, and explore alternative treatments.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...